Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.

Christie CD, Duncan ND, Thame KA, Onorato MT, Smith HD, Malcolm LG, Itzler RF, Dinubile MJ, Heaton PM.

Pediatrics. 2010 Dec;126(6):e1499-506. doi: 10.1542/peds.2010-1240. Epub 2010 Nov 29.

PMID:
21115586
2.

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.

Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M.

Pediatr Infect Dis J. 2010 Oct;29(10):957-63. doi: 10.1097/INF.0b013e3181e28e6e.

PMID:
20442684
3.

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.

Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ; REST Study Team.

Pediatr Infect Dis J. 2007 Dec;26(12):1099-104.

PMID:
18043445
4.

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S29-35. doi: 10.1016/S1201-9712(07)60019-8.

5.

Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine.

Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, Parashar UD.

Pediatrics. 2009 Mar;123(3):744-9. doi: 10.1542/peds.2008-1200.

PMID:
19254997
6.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041. Epub 2009 Oct 29.

PMID:
19879226
7.

Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.

Bégué RE, Perrin K.

Pediatrics. 2010 Jul;126(1):e40-5. doi: 10.1542/peds.2009-2069. Epub 2010 Jun 29.

PMID:
20587671
8.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M.

Eur J Pediatr. 2010 Nov;169(11):1379-86. doi: 10.1007/s00431-010-1242-3. Epub 2010 Jun 18.

9.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team.

N Engl J Med. 2006 Jan 5;354(1):23-33.

10.

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.

Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, Mast TC, Staat MA.

Hum Vaccin. 2011 Jul;7(7):734-48. doi: 10.4161/hv.7.7.15511. Epub 2011 Jul 1. Review.

PMID:
21734466
11.

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.

Ciarlet M, Schödel F.

Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Review.

PMID:
20006144
12.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
13.

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.

Clark HF, Offit PA, Plotkin SA, Heaton PM.

Pediatr Infect Dis J. 2006 Jul;25(7):577-83. Review.

PMID:
16804425
14.

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatrics. 2010 Feb;125(2):e208-13. doi: 10.1542/peds.2009-1246. Epub 2010 Jan 25.

PMID:
20100757
15.

Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial.

Bernstein D.

Pediatrics. 2008 Jan;121(1):223; author reply 223-4. doi: 10.1542/peds.2007-1896. No abstract available.

PMID:
18166579
16.

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.

Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD.

Pediatrics. 2010 Feb;125(2):e199-207. doi: 10.1542/peds.2009-1021. Epub 2010 Jan 18.

PMID:
20083525
17.

Effects of vaccine on rotavirus disease in the pediatric population.

Dennehy PH.

Curr Opin Pediatr. 2012 Feb;24(1):76-84. doi: 10.1097/MOP.0b013e32834ee594. Review.

PMID:
22189398
18.

Rotavirus vaccines: targeting the developing world.

Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6.

PMID:
16088799
19.

Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.

Goveia MG, Suprun L, Itzler RF, McFetridge R, Dallas MJ, Kuter BJ.

Pediatr Infect Dis J. 2010 Mar;29(3):263-5. doi: 10.1097/INF.0b013e3181be6257.

PMID:
19949360
20.

Rotavirus vaccines: safety, efficacy and public health impact.

Gray J.

J Intern Med. 2011 Sep;270(3):206-14. doi: 10.1111/j.1365-2796.2011.02409.x. Epub 2011 Jul 3.

Supplemental Content

Support Center